Despite encouraging clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from PBMs. These companies are typically erecting obstacles to access, including high cost criteria and prior authorization that hinder user availability. Analysts believe that th… Read More